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Activation of the PKB/AKT Pathway by ICAM-2
ecules in lymphoid cells, such as those that can antagonizeOmar D. Perez,1,2,3 Shigemi Kinoshita,1,2,3
cell death or override growth inhibition programs, wouldYasumichi Hitoshi,3,4 Donald G. Payan,4
be pivotal in understanding intrinsic cell survival programsToshio Kitamura,5 Garry P. Nolan,1,2,3,6
that go awry in some lymphatic disorders or contribute toand James B. Lorens3,4,6
metastatic spread of some oncologies.1 Department of Microbiology and Immunology
Functional characterization of molecules involved in2 The Baxter Laboratory of Genetic Pharmacology
cellular adhesion that contribute to ECM survival signals3 Department of Molecular Pharmacology
has been focused on signal transduction pathways acti-Stanford University School of Medicine
vated by integrins and cadherins. ICAM-2 (CD102) is aStanford, California 94305
member of the Ig superfamily of cell surface proteins4 Rigel, Incorporated
and mediates leukocyte binding to LFA-1 (CD11a/CD18)240 East Grand Avenue
and MAC-1 (CD11b/CD18) (van Kooyk and Figdor, 2000).South San Francisco, California 94080
As a cell surface adhesion protein involved in leukocyte5 Institute of Medical Science
recruitment in tissues, ICAM-2 is expressed in low levelsDepartment of Hematopoietic Factors
on most leukocytes including T and B lymphocytes,University of Tokyo
monocytes, platelets, and early CD34 hematopoieticTokyo 108-8639
progenitor cells (de Fougerolles et al., 1991; Diacovo etJapan
al., 1994). Based on the expression pattern of ICAM-2,
it has been postulated to be involved in lymphocyte
recirculation, trafficking, and extravasation. Studies ofSummary
ICAM-2-deficient mice support this by demonstrating
that eosinophil trafficking is augmented in inflammatoryWe identified intracellular adhesion molecule-2
responses (Gerwin et al., 1999). Surprisingly, this pheno-(ICAM-2) in a genetic screen as an activator of the
type is relatively mild considering the range of cell typesPI3K/AKT pathway leading to inhibition of apoptosis.
upon which ICAM-2 is expressed. Thus, it is likely theICAM-2 induced tyrosine phosphorylation of ezrin and
ICAM-2-deficient mice do not sufficiently detail the rolesPI3K kinase membrane translocation, resulting in
of ICAM-2, warranting further characterizations of thephosphatidylinositol 3,4,5 production, PDK-1 and AKT
mechanisms by which ICAM-2 acts are needed.activation, and subsequent phosphorylation of AKT
In contrast to ICAM-2’s putative role as an adhesiontargets BAD, GSK3, and FKHR. ICAM-2 clustering pro-
molecule, it is surprising to find ICAM-2 highly expressedtected primary human CD19 cells from TNF- and
in lymphomas and CD5B cells from B cell chronic lym-Fas-mediated apoptosis as determined by single-cell
phatic leukemia (B-CLL) patients (Molica et al., 1996;analysis. ICAM-2 engagement by CD19 cells of its
Renkonen et al., 1992). Recent gene expression profilingnatural receptor, LFA-1, on CD4 naive cells specifi-
of large B cell lymphomas from patients indicated ancally induced AKT activity in the absence of an MHC-
elevated expression of ICAM-2 (Alizadeh et al., 2000).peptide interaction. These results attribute a novel
Interestingly, ICAM-2 is the only ICAM (of ICAMs 1–5)signaling function to ICAM-2 that might suggest mech-
that maps to chromosome 17q23-25 (Sansom et al.,anisms by which ICAM-2 signals intracellular commu-
1991), a segment associated with genomic instabilitynication at various immunological synapses.
and recently identified as a segment of high aberration
in various cancers (Dion et al., 2000). Despite these ob-Introduction
servations, ICAM-2’s role and molecular characteriza-
tion in the progression of lymphatic disease states has
A cell’s commitment to cellular proliferation or pro- not been addressed.
grammed cell death is a balance of the survival and We devised a retrovirally based genetic screen to
death signals communicated from both the immediate identify genes that are involved in regulation of apopto-
environs, such as extracellular matrix (ECM) interac- sis. One recovered cDNA encoded full-length intracellu-
tions, cell-cell contact, or more distant sites through lar adhesion molecule-2 (ICAM-2). Here, we show that
endocrine and paracrine factors (Ruoslahti and Reed, ICAM-2 is a mediator of cell survival signals initiated
1994). A lack of survival signals leading to apoptosis is through interaction with its endogenous receptor leuko-
exemplified in the phenomenon of anoikis, where epithe- cyte function-antigen-1 (LFA-1). ICAM-2 mediates a sur-
lial cells undergo apoptosis when ECM attachment is vival signal sufficient to block apoptosis by activation
blocked (Frisch and Ruoslahti, 1997). ECM survival sig- of the PI3K/AKT pathway, contingent on ezrin activation
nals are presumably mediated by activation of cell-sur- by Src tyrosine phosphorylation and Rho-kinase-depen-
face receptors via integrin clustering and contribute to dent threonine phosphorylation. Ezrin activation recruited
the specificity of cell-cell/cell-matrix interactions. De- PI3K to the cell membrane in lymphoid cells, thereby
regulation of ECM-integrin signaling can lead to anchor- initiating activation of the PI3K/AKT pathway. Multipa-
age-independent growth. Identification of analogous mol- rameter FACS analysis confirmed ICAM-2 clustering led
to phosphatidylinositol 3,4,5 production and AKT activ-
ity in CD19 primary human cells and subsequent pro-6 Correspondence: gnolan@stanford.edu (G.P.N.), jblorens@rigel.
com (J.B.L.) tection from Fas- and TNF-mediated apoptosis. The find-
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ings underscore a novel positive role for ICAM-2 in (B-CLL) (Molica et al., 1996), prompted us to test the
antiapoptotic activity of ICAM-2 in the mouse pre-B cellsignaling pathways involving Src/Rho-Kinase/Ezrin/PI3K/
PDK-1/AKT and downstream effectors upon LFA-1 en- line, 70Z/3. ICAM-2 expression inhibited STP-induced
apoptosis in 70Z/3 cells (Figures 2A and 2B). We as-gagement. The results have implications for ICAM-2 inter-
action with other ligands such as DC-SIGN and MAC-1. sessed the ability of ICAM-2 expression to protect fac-
tor-dependent cells from factor withdrawal. ICAM-2 ex-
pression in the IL-3-dependent pro-B cell line BaF3Results
resulted in a delayed onset of apoptosis following IL-3
deprivation (Figure 2B). Furthermore, ICAM-2 rescuedScreening a Retroviral cDNA Library
BaF3 cells from apoptosis induced by treatment within an Antiapoptotic Functional Assay
anti-Fas antibodies (Figure 2B). These results are com-We devised a retroviral cDNA library screen to identify
parable to transduction controls using Bcl-2. We notecDNAs that alter apoptotic signaling (Figure 1A). cDNAs
there is cell specificity to the antiapoptotic effect: Jurkatfrom Jurkat T cells were screened for antiapoptotic func-
T cells overexpressing ICAM-2 were not protected fromtion in a recipient nontransformed (fibroblast) cell. Apo-
apoptosis induced by Fas engagement but were fromptosis was induced with staurosporine (STP), a kinase-
STP induction (Figure 2B). However, we later provideinhibiting plant-derived alkaloid that is a potent inducer
evidence for a physiologic function of ICAM-2 in Jurkatof cell death in the transduced cell culture (Figure 1A
cells as we observe that specific ligation of endogenousand see Experimental Procedures). Surviving cell clones
ICAM-2 on Jurkat cells is sufficient to block Fas-inducedwere expanded, replated, and retreated with STP. The
apoptosis (described below).complexity of the remaining library of expressed cDNAs
The initial cDNA screen was performed in fibroblasts,in the surviving population was assessed with RT-PCR.
and it is therefore unlikely that ICAM-2’s antiapoptoticA few major bands were observed following three
effect was mediated through interaction with its lympho-rounds of selection (Figure 1B).
cyte-specific integrin ligand, LFA-1 (CD11a/CD18), sinceTrue phenotype-inducing clones were verified by a
NIH3T3 do not express LFA-1 (data not shown). To de-Moloney murine leukemia virus (MMLV) phenotypic
termine whether ICAM-2 initiated the signal through en-transfer assay (see Experimental Procedures). Reappli-
gagement of another surface protein’s extracellular do-cation of the STP selection process in MMLV phenotype-
main or sent the signal from its own intracellular region,transferred NIH3T3 cells enriched antiphenotypic clones
we prepared an extracellular domain-deleted (N) ver-at a rate of one/background. Three of the pooled libraries
sion of ICAM-2 and transduced it into BaF3 cells. Ex-showed enrichment for specific bands after PCR (see
pression of the cytoplasmic domain at the cell surfaceFigure 1B, lanes 1 and 2, for an example). Several bands
was sufficient to impart full antiapoptotic activity (Figurewere rescued by PCR cloning, and one of these bands
2B). We sought then to determine the signaling pathwaywas sequenced and demonstrated to encode full-length
by which ICAM-2 conferred resistance to apoptosis.ICAM-2 cDNA (Staunton et al., 1989), an immunoglobulin
superfamily member that regulates leukocyte adhesion
through interaction with its integrin counterreceptor, The ICAM-2 Survival Function Maps
LFA-1 (de Fougerolles et al., 1991; Simmons, 1995). to a Membrane-Cytoskeleton Linker
Protein Binding Motif
ICAM-2 connects to the actin cytoskeleton by linkerICAM-2 Mediates a Survival Signal
The ICAM-2 cDNA was cloned into a retroviral vector proteins -actinin (Heiska et al., 1996; Helander et al.,
1996) and ezrin, a member of the ezrin/radixin/moesin(pBMN-Z-IN) that carries an internal ribosome entry site
(IRES) upstream of the neomycin resistance gene. Ex- (ERM) cytoplasmic linker protein family (Yonemura et
al., 1998), through their binding to the cytoplasmic domainpression of the 60 kDa ICAM-2 glycoprotein in neomycin-
selected NIH3T3 fibroblasts infected with the pBMN-Z- of ICAM-2. To assess the potential role of C-terminal
interacting proteins in mediating the ICAM-2 antiapo-IN-ICAM-2 construct was verified by immunoblotting
(Figure 1C), flow cytometry (Figure 1D), and immunopre- ptotic signal, the ezrin/-actinin recognition sequence
was mutated to a scrambled sequence unable to bindcipitation (see also Figure 3B). The expressed ICAM-2
protein comigrated with the native protein from Jurkat -actinin in vitro (Heiska et al., 1996). NIH3T3 cells ex-
pressing ICAM-2, ICAM2-C, or ICAM2-C-mut(ezrin/T cells (data not shown).
STP treatment is thought to mimic factor withdrawal in -actinin) proteins were prepared and assayed for sur-
vival following both etoposide and STP treatment.cells (Raff, 1992) and induces, at nanomolar concentra-
tions, apoptosis by inhibiting PKC, PKA, and PKG among ICAM-2 imparted survival on NIH3T3 cells, which was
lost when the C-terminal deletion of ICAM-2 (ICAM2-other kinases. ICAM-2 expression in NIH3T3 cells limited
the extent of apoptosis induced by STP treatment as de- C) was expressed in cells (Figure 3A). Mutation of the
ezrin/-actinin binding site in the ICAM-2 cytoplasmictermined by an annexin-V binding assay (Figure 2A), pyk-
notic nuclei count (Figure 2B), and the BrdU TUNEL assay tail also abrogated protection against etoposide or STP
treatments. Confirming this interaction, both -actinin(data not shown), confirming the clone’s selection by
phenotype in the screen. ICAM-2-overexpressing Jurkat and ezrin coimmunoprecipated with full-length ICAM-2
(Figure 3B), suggesting that one or both of these cy-T cells did not inhibit apoptosis across a range of con-
centrations of a monoclonal antibody (mAb) to the Fas toskeleton linker proteins may relay the antiapoptotic
signal (see below).receptor, contrasting inhibition of STP-induced apopto-
sis (Figure 1E, panels 2–3, elaborated below). As survival signaling through many adhesion molecules
involves PI3 kinase (Frisch and Ruoslahti, 1997), we ana-A report correlating ICAM-2 expression with a lympho-
proliferative disorder, B cell chronic lymphatic leukemia lyzed the role of this pathway in induction of the ICAM-2
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Figure 1. Retroviral Library Screen for Antiapoptotic Molecules to Staurosporine-Induced Apoptosis Identifies ICAM-2
(A) Retroviral cDNA library screen used to isolate ICAM-2 as an antiapoptotic gene. SD refers to the deleted splice donor site.  refers to
the Psi packaging sequence.
(B) RT-PCR complexity of populations surviving STP-induced apoptotic screen. Surviving population (1) exhibited several discrete bands
and the posttransfer population (2) exhibited a single band. M, molecular weight marker. A negative control vector (LacZ) initially spiked into
the library at 10% was undetectable, while an independent infection of a Bcl-2-expressing vector was readily detected.
(C) Retroviral ICAM-2 expression analysis in infected NIH3T3 by Western.
(D) Retroviral vector encoding ICAM-2 ectopically expresses surface ICAM-2 on BaF3 pro-B-cells (right panel) and HUVEC cells (left panel)
as detected by flow cytometry.
(E) Dose response curves of ICAM-2-transduced NIH3T3 and Jurkat T cells to treatment of STP or anti-Fas antibody (24 hr). Open squares,
ICAM-2 expressing cells; Closed squares, control cells expressing vector alone. The percentage of apoptotic cells is expressed as the mean
(bar)  SD of triplicate cultures.
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Figure 2. Overexpression of ICAM-2 Results in a Broadly Acting Antiapoptotic Phenotype
(A) ICAM-2 and vector control expressing NIH3T3 were subjected to an annexin-V binding assay in the presence or absence of STP (1 M,
24 hr).
(B) Effects of ICAM-2 overexpression in Jurkat, NIH3T3, 70Z/3, and BaF3 cells in the context of different apoptotic inducers. Infected cells
were treated with either STP (1 M) or anti-Fas antibody (5 g/ml), or deprived of IL-3 for 24 hr as indicated and evaluated for apoptosis.
Cells were infected with retroviral constructs encoding ICAM-2, ICAM2-N, vector control, or Bcl-2 and induced to apoptose as indicated
(24 hr, 70Z/3 cells: 0.2 M STP, 4 hr). The percentage of apoptotic cells is expressed as the mean (bar)  SD of triplicate cultures.
antiapoptotic signal. Pretreatment of ICAM-2-expressing more relevant ICAM-2 induction signal than ICAM-2 ov-
erexpression. Quantitative FACS analysis revealed thatBaF3 cells with the PI3 kinase inhibitor wortmannin
blocked the ICAM-2-mediated antiapoptotic effect (Figure the density of ICAM-2 molecules on the cell surface vary
3C, left panel). Similarly, treating ICAM-2-transduced widely between cell types (Figure 4A). Basal expression
NIH3T3 with the inhibitor LY294002 abrogated the anti- levels of ICAM-2 on lymphocytes was 2–4 orders of
apoptotic effect of ICAM-2 as measured by both magnitude less than that from retroviral vector expres-
annexin-V binding (Figure 3C) and the BrdU TUNEL sion of ICAM-2. Jurkat cells were chosen for further
assay using flow cytometry (data not shown). Thus, PI3 study as they fell in the mid-range of ICAM-2 expression
kinase was implicated in the ICAM-2 survival signaling. and have been used extensively as a model for T cell
function.
We crosslinked (clustered) endogenous Jurkat T cellICAM-2 Ligation Induces Ezrin Phosphorylation,
PDK-1 Activation, and Translocation of PI3K ICAM-2 surface molecules with monoclonal antibodies
(mAbs) to mimic receptor engagement. Ezrin associatedand AKT to the Membrane
We postulated that antibody crosslinking could emulate with ICAM-2 at basal levels, but increased this associa-
tion and became tyrosine phosphorylated as a functionICAM-2’s interaction with its receptor(s), providing a
ICAM-2 Activates AKT
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Figure 3. PI3-Kinase Is Necessary for the ICAM-2 Antiapoptotic Effect
(A) The C terminus is required for survival. ICAM-2, wild-type sequence; ICAM-2C, cytoplasmic domain deletion; ICAM-2 C-scrambled, full-
length with scrambled -actinin binding site were incubated with etoposide (100 M, 24 hr) and scored for viability post 24 hr. The percentage
of surviving cells is expressed as the mean (bar)  SD of triplicate cultures. Flow cytometry detection of extracellular N terminus is presented
on the left and indicated by appropriate construct.
(B) ICAM-2 interacts with -actinin and ezrin. ICAM-2, ICAM2-C, or control cells were immunoprecipitated for ICAM-2 and immunoblotted
for either -actinin or ezrin.
(C) Pharmacological inhibitors of PI3K abrogate ICAM-2’s antiapoptotic effect. ICAM-2- or vector-transduced BaF3 cells were treated with
STP (1 M) with (unfilled) or without (filled) the addition of 100 nM wortmannin for 24 hr (left bar graph). Apoptosis was determined by annexin-V
binding. The proportion of apoptotic cells in each culture without STP was 8%  2. The percentage of apoptotic cells is expressed as the
mean (bar)  SD of triplicate cultures. ICAM-2-, ICAM2-C-, or vector-transduced NIH3T3 were treated with STP (1 M) in the presence or
absence of 10 M LY294002 for 24 hr (right bar graph). The percentage of apoptotic cells is expressed as the mean (bar)  SD of triplicate
cultures.
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Figure 4. Ligation of Endogenous ICAM-2 Induces Tyrosine Phosphorylation of Ezrin and Recruits PI3K to the Membrane, Resulting in PDK-1
and AKT Kinase Activation
(A) Quantitative assessment of ICAM-2 surface expression across cell lines of different origins. The number of surface molecules/cell is
expressed as the mean (bar)  SD of triplicate experiments.
(B) Crosslinking of endogenous ICAM-2 induces ezrin tyrosine phosphorylation and enhanced ICAM-2 interaction. Jurkat cells were crosslinked
for ICAM-2 using mAb for the indicated times and subjected to immunoprecipitation/immunoblotting (labeled as IP and IB, respectively) as
indicated.
(C) Ezrin phosphorylation and enhanced interaction with the p85 subunit of PI3K as a function of ICAM-2 determined as described above.
(D) Coimmunoprecipitation of PI3K and -actinin interacting proteins as induced by ICAM-2 crosslinking in Jurkat cells (as described above)
and determined by immunoblotting (IB) as indicated.
(E) PI3K membrane localization and preferential interaction with ezrin as a function of ICAM-2 ligation per time.
(F) PDK-1 kinase activity assay. PDK-1 kinase was immunoprecipitated from ICAM-2 crosslinked cells as a function of time and subjected to
an in vitro kinase assay and presented as counts per min (CPM).
(G) AKT membrane localization as a function of ICAM-2 ligation in membrane/cytosolic fractions of Jurkat cells.
ICAM-2 Activates AKT
57
of ICAM-2 crosslinking (Figure 4B). Peak phosphory- Phosphorylated Ezrin as a Mediator of ICAM-2-
Induced Signal Transductionlation was reached at the 15 time point. Although
-actinin associated with ICAM-2 (Figure 3B), no phos- In order to identify upstream kinases capable of tyrosine
phosphorylation of ezrin as a function of ICAM-2 ligation,phorylation of -actinin was observed (data not shown).
Ezrin phosphorylation is likely mediated by a membrane we used a phosphotyrosine-protein-based ELISA to
screen for the inhibition of ezrin tyrosine phosphoryla-proximal protein tyrosine kinase (see below) since
ICAM-2 lacks any known tyrosine kinase domains or tion by various known inhibitors of protein kinases. Of
the inhibitors screened, herbimycin A, a potent inhibitoractivity.
Phosphorylation of ezrin by intracellular kinases can of src tyrosine kinase family members src and p62yes,
was found to inhibit tyrosine phosphorylation of ezrin,mediate PI3 kinase membrane localization (Gautreau et
al., 1999; Ng et al., 2001). We observed increased ezrin comparable to genistein, which served as a control for
general tyrosine kinase inhibition (Figure 5C). Surpris-association with the p85 regulatory PI3K subunit at 30
min as a function of ICAM-2 crosslinking (Figure 4C, ingly, we also found inhibitors of ROCK, a Rho-depen-
dent serine/threonine kinase (Y-27632), inhibitors ofpanel i) as well as a reproducible loss of PI3K p110
catalytic subunit association with ICAM-2 (Figure 4C, GTPases, and inhibitors of phosphoinositide turnover
(Psi-Tectorigenin) to inhibit the tyrosine phosphorylationpanel ii) that persisted at longer time points studied
(data not shown). Immediately after induction, there of ezrin, with minor affects by PKC isozyme inhibitors
bisindolymaleimide I and II. Given that the assay waswere increases in both threonine and tyrosine phosphor-
ylation of ezrin (Figure 4C, panels iii and iv). ICAM-2 designed to detect tyrosine residue phosphorylation,
activation of Rho-dependent processes may be a pre-crosslinking induced an association of -actinin and
ezrin with PI3K (Figure 4D, left panel) and a weak interac- requisite for ezrin to be tyrosine phosphorylated by src
kinase (see below).tion between PI3K and -actinin when -actinin was
used as the precipitating antibody (Figure 4D, right We had observed that overexpression of ICAM-2 was
not sufficient to block Fas-induced apoptosis in Jurkatpanel). The induction of tyrosine phosphorylation of ez-
rin and its concomitant association with PI3K in recipro- T cells (Figures 1E and 2C). Contrary to this, we observed
that crosslinking of endogenous ICAM-2 on Jurkatcal coimmunoprecipitations suggest ezrin might be a
crucial cytoplasmic linker between ICAM-2 and PI3K in T cells protected against Fas-induced apoptosis (Figure
5D). This suggested that ICAM-2 clustering can impartJurkat T cells (supported further below).
Upon activation, PI3K translocates to the membrane a cell survival signal that overexpression cannot mimic
in these cells. Notably, this effect was abrogated in theto phosphorylate its membrane-bound phospholipid
substrate phosphatidylinositol 4,5 bisphosphate (PIP2) presence of GTP	S, Psi-tectorigenin, Y-27632, and her-
bimycin A. Furthermore, functional ablation of the ICAM-to phosphatidylinositol 3,4,5 (PIP3) (Blume-Jensen and
Hunter, 2001). Production of PIP3 by PI3K serves as a 2-induced cell survival signal by inhibitors GTP	S, Psi-
tectorigenin, Y-27632, and herbimycin A in lymphoidsecond messenger to recruit pleckstrin domain-con-
taining proteins, such as AKT, to the plasma membrane cells (which all blocked ezrin phosphorylation) further
supports the contention that phosphorylated ezrin linksand serves to activate other kinases, namely phospha-
tidylinositol-dependent kinases (PDK-1 and PDK-2), ICAM-2 to PI3K activation.
which are themselves critical activators of AKT. We
crosslinked endogenous ICAM-2 on Jurkat cells and ICAM-2 Crosslinking Protects Primary CD19 B Cells
found this resulted in the rapid association of the PI3K from TNF- and Fas-Induced Apoptosis
p110 subunit with the membrane fraction (Figure 4E). via PI3K/AKT Activation Distinctly from
After crosslinking of ICAM-2, there was a time-depen- ICAM-1, ICAM-3, CD43, and CD44
dent increase in PDK-1 activity (Figure 4F), concomitant To study biochemical events related to this signaling
with a membrane translocation of AKT (Figure 4G). pathway in heterogeneous primary cell populations, we
We followed the status of AKT substrate molecules applied procedures for single-cell analysis of intracellu-
after ICAM-2 crosslinking in Jurkat T cells as a function lar active kinases by flow cytometry (Perez and Nolan,
of time to monitor post-AKT activation effects (Figure 2002). We similarly applied FACS-based methodologies
5A). ICAM-2 ligation in Jurkat cells led to rapid AKT for phosphatidylinositol 3,4,5 triphosphate (PIP3) and
phosphorylation and demonstrable AKT kinase activity phosphatidylinositol 4,5 bisphosphate (PIP2) detection,
in vitro (Figure 5A, left panels i–iii). GSK and FKHR were reflective of phospholipid turnover within single cells
both rapidly phosphorylated by 30 min, as expected (O.D.P. and G.P.N., unpublished data). We applied FACS-
after AKT activation in these cells (Figure 5A, left panels based AKT kinase assays and PIP3/ PIP2 measurements
iv and v). AFX showed constitutive phosphorylation in for two purposes: (1) to test the physiological relevance
Jurkat cells. Phosphorylation of BAD at serine 136 and of ICAM-2 signaling in complex primary immune system
serine 112 was also observed as a function of ICAM-2 cell populations and (2) to observe intracellular AKT acti-
(Figure 5A, right panel set). ICAM-2 crosslinking pro- vation and PIP3/PIP2 conversion when ICAM-2 ligated
tected Jurkat T cells from STP-induced apoptosis, veri- to LFA-1 on the surface of an apposing cell.
fying the resultant outcome of the PI3K/AKT pathway Human PBMC were crosslinked for anti-ICAM-2 anti-
activation (Figure 5B). Incubation with LY294002 abro- body prior to treatment with TNF and anti-Fas mAb.
gated the antiapoptotic effects initiated by crosslinking Treated PBMC were subjected to flow cytometry, gated
ICAM-2 in Jurkat T cells (data not shown). Similar results by immunophenotypes for CD4 (T cell) and CD19 (B cell),
were obtained in crosslinking ICAM-2 in Baf3 pro-B cells and subsequently assayed for AKT activity and apopto-
sis by multiparameter FACS. Intracellular active AKT(data not shown).
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Figure 5. Ligation of Endogenous ICAM-2-Induced AKT Activation in Lymphoid Cells Conferring Cell Survival
(A) ICAM-2 crosslinking induced AKT activity in Jurkat T cells and subsequent phosphorylation of GSK3, FKHR, and BAD as a function of
time. Serum-starved Jurkat T cells were incubated (isotype control or anti-human ICAM-2 [10 g/ml]) for the indicated times. Immunoblot
analysis verified AKT dual phosphorylation and FKHR and GSK3 phosphorylation (left panel). Total BAD protein was immunoprecipitated and
subsequently immunoblotted with phospho-specific antibodies as indicated as a function of ICAM-2 crosslinking (right panel).
(B) ICAM-2 clustering on Jurkat T cells treated with STP (1 m, 6 hr). 106 Jurkat T cells ICAM-2 were ICAM-2 crosslinked (mAb 10 g/ml, 30
min) prior to treatment with STP () or DMSO vehicle (
) and assessed for apoptosis.
(C) Inhibition of ezrin phospho-tyrosine by chemical inhibitors of src and Rho-dependent kinases.
(D) ICAM-2 survival signal is abrogated in the presence of GTP	S, Psi-tectorigenin, Y-27632, and herbimycin A. Jurkat cells were incubated
with indicated inhibitor (10 M, 1 hr) prior to being crosslinked for ICAM-2 (10 g/ml, 1 hr) and treated with anti-Fas (50 ng/ml, 8 hr). Cells
were assessed for apoptosis by annexin-V binding assay.
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measurements were achieved using a phospho-specific activated AKT upon mixing with CD4 cells. Critically,
this could be inhibited by prior treatment of T cells withfluorescent probe for the AKT-phospho Ser473 phos-
phorylation site on AKT detectable by FACS (Perez and LFA-1 and 2 mAbs (Figure 6F). Incubation with MAC-1
(control) on CD4 T cells had no effect on the AKT levelsNolan, 2002). Both CD4T cells and CD19B cells exhib-
ited AKT activity when ICAM-2 was clustered, and in- of the CD19population. Blocking ICAM-1 on the CD19
cells presented a minimal decrease in detected phos-duced AKT activity preferentially protected B cells from
apoptosis to Fas- and TNF-induced apoptosis (Figure pho-AKT, congruent with above results that ICAM-1
crosslinking did not activate AKT. Blockade with either6A; similar results were obtained with Jurkat cells, data
not shown). There was little apparent antiapoptotic ef- ICAM-2 or ICAM-3 partially decreased phospho-AKT
upon CD4 T cell interaction. Complete abrogation offect on primary CD4 T cells, perhaps due to the fact
that these T cells were not strongly induced by Fas or phospho-AKT was not expected since prolonged incu-
bation with ICAM-2 or ICAM-3 antibodies at 37C canTNF to undergo apoptosis under our conditions—as
quiescent primary CD4 T cells require prior stimulation activate AKT (see Figure 6C). The levels of phospho-
AKT in the presence of mAbs to ICAM-2 and ICAM-3with IL-2 or PMA/ionomycin to become susceptible to
apoptosis under these activation regimes (data not were 4-fold higher than unmixed CD19 cells (Figure
6F) and about 2-fold higher in CD19 cells incubatedshown). Protection from apoptosis in primary B cells
correlated perfectly with AKT phosphorylation at serine with mAbs to ICAM-2 and ICAM-3 in the absence of
CD4 cell mixing under the same experimental condi-473, confirming prior roles for this target serine in the
protective effect of AKT against Fas- and TNF-induced tions (data not shown).
apoptosis. Therefore, in the absence of an MHC-antigen interac-
Crosslinking of ICAM-2 activated conversion of PIP2 tion, ICAM-2, and apparently ICAM-3, can signal to AKT
to PIP3 in the CD19 cell population (Figure 6B). ICAM-1, upon interaction with at least LFA-1. The levels of AKT
a known ezrin binding surface molecules, did not induce activity upon ICAM-2 interaction with LFA-1 in this inter-
PIP2 conversion or have an effect on phosphoinositide lymphocyte reaction is lower than that achieved by
levels upon crosslinking (Figure 6B). These results corre- crosslinking of the ICAM-2 and ICAM-3 molecules with
late with PI3K activity profiles and membrane localiza- mAbs at 37C (see Figure 6C). It is also apparent that
tion shown above. Interestingly, ICAM-3 increased both blockade of LFA-1 and 2-integrin did not completely
PIP3 and led to the disappearance of a population of abrogate the phospho-AKT levels in the CD19 popula-
cells with low levels of PIP2 (Figure 6B). tion. Taken together, these observations suggest that
We considered whether other ezrin binding proteins, although the ICAM-2/LFA-1 interaction is not solely re-
such as ICAM-3, CD44, and CD43 signaled similarly to sponsible for activating AKT in the ICAM-2 expressing
ICAM-2. ICAM-2, -3, CD44, and CD43 but not ICAM-1 cells, there exist other interacting molecules that can
activated AKT in primary CD19 cells to varying extents signal into the same network (such as ICAM-3). Thus,
(Figure 6C). ICAM-1 did not activate AKT. However, only the ICAM-2/LFA-1 interaction represents an important
ICAM-2 and ICAM-3 effectively blocked TNF- or Fas- fraction of the signals initiated at the T-B cell interface.
induced apoptosis (Figure 6D) in CD19 B cells. This As studied here, we have focused upon those signals
ICAM-2-induced antiapoptotic effect was abrogated by entering the B cell side of the synapse.
incubation with Psi-tectorigenin and Y-27632 in CD19
human B cells (Figure 6E), verifying the Rho-kinase and
phosphoinositide dependency in primary human cells Discussion
(incubation with GTP	S loading conditions and herbi-
mycin A-induced apoptosis in primary cells for unknown The results demonstrate that ICAM-2 can activate a po-
reasons, data not shown). Thus, ICAM-2 oligomerization tent intracellular signaling system. ICAM-2-induced AKT
leads to the apparent membrane recruitment of PI3- activation is a survival signal that can render a cell resis-
kinase and results in PIP3 production and subsequent tant to chemical (STP and etoposide) and physiological
activation of AKT kinase, protecting Jurkat cells and (TNF and Fas ligand) apoptotic inducers and is contin-
human primary lymphoid B cells from apoptosis. gent on ezrin activation and a tyrosine phosphorylation
event appearing to require both the src tyrosine kinase
and the Rho-dependent serine/threonine kinase. This
results in PI3K recruitment to the plasma membrane,ICAM-2 Interaction with Its Natural Receptor
LFA-1 Activates AKT PIP3 production, and subsequent activation of AKT,
which is capable of initiating a variety of cell survivalWe tested whether ICAM-2 oligomerization, by virtue of
interacting with its natural receptor, LFA-1, was suffi- signals through phosphorylation of downstream targets.
This signal can be initiated when a primary B cell en-cient to activate the PI3K/AKT pathway. We tested this
by mixing purified populations of CD19 cells (B cells) counters a primary T cell in the absence of an MHC-
dependent T cell receptor ligation.with CD4cells (T cells) and assessed intracellular phos-
pho-AKT in immunophenotyped populations by flow cy- We focused on the ability of ezrin to mediate the signal
in lymphoid cells since ezrin was phosphorylated as atometry. Samples were incubated in the presence or
absence of ICAM-1, -2, -3, LFA-1, MAC-1, and 2 integ- function of ICAM-2 crosslinking (Figures 4B and 4C)
and since there was no observed phosphorylation orrin mAbs (surface stained at 4C) prior to cell mixing in
order to assess specificity of the adhesion molecules detectable modification of -actinin (data not shown).
This suggested an ICAM-2-induced ezrin activationresponsible for the detected phospho-AKT. CD19 cells
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Figure 6. Ligation of ICAM-2 and Interaction with LFA-1 Induces AKT Activity and Protects Primary B Cells from Apoptosis
(A) Multiparameter FACS analysis illustrates ICAM-2-induced AKT activity in CD4 and CD19 populations protects from apoptosis.
(B) PBMC were crosslinked for ICAM-1, -2, -3, CD43, or CD44 (10g/ml, 45 min) and subjected to phosphatidylinositol detection of phosphatidyl-
inositol 3,4,5 triphosphate (PIP3) and phosphatidylinositol 4,5 bisphosphate (PIP2).
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Figure 7. Model for ICAM-2-Mediated Cell Survival Signal
ICAM-2 oligomerization enhances ezrin’s affinity with ICAM-2 and results in phosphorylation of ezrin through a Src/Rho-dependent mechanism.
Ezrin’s interaction with the p85 regulatory subunit of PI3K results in recruitment of PI3K to the membrane. Membrane translocation of PI3K
generates PIP3 that activate PDK-1 and recruit AKT to the plasma membrane by binding to its PH domain. Translocation of cytosolic AKT to
the membrane allows PDK1/2 to phosphorylate AKT at Ser473 and Thr308, activating AKT. AKT subsequently phosphorylates downstream
effectors GSK3, BAD, and FKHR (and potentially others depending on the cell type). Phosphorylation of these effectors can block apoptosis
alone or synergistically to generate a survival signal.
mechanism. The ICAM-2 cytoplasmic domain interacted pose that ICAM-2 mediates a cell survival signal through
a Rho-dependent ezrin activation. This initiates PI3Kwith ezrin, a member of the ezrin/radixin/moesin (ERM)
family of membrane-cytoskeleton linker proteins (Hel- recruitment to the membrane and resultant PIP3-induced
PDK-1 and AKT activity.ander et al., 1996) (Figures 3B and 4B–D). ERM-proteins
regulate cell morphology, adhesion, and growth by pro- Current views on the activating mechanisms of ezrin
report a variety of differences among different cell types.moting membrane-cytoplasmic linkages (Tsukita and
Yonemura, 1997). Interestingly, ezrin overexpression A two-step activation process has been proposed for
ezrin (Bretscher et al., 2000, and references therein).has been shown to induce ICAM-2 clustering (Helander
et al., 1996), suggesting that inappropriate surface pro- ERM proteins are believed to reside in a dormant closed
conformation mediated by C- to N-terminal interaction.tein clustering and subsequent signaling can be strongly
influenced by ERM proteins. Phosphorylation at threonine residues induces a confor-
mational change that unmasks the F-actin binding sitesICAM-2 clustering induced ezrin tyrosine phosphory-
lation and enhanced threonine phosphorylation, con- in the C and N termini (Bretscher et al., 2000). RhoGDI
(Rho-GDP-dissociation inhibitor) has been observed tocomitant with an increase in p85 and PI3K association
in Jurkat T cells at later time points (Figure 4C). This was bind only activated ERM proteins (Takahashi et al.,
1998), suggesting that dissociation of Rho/RhoGDI is asufficient to translocate PI3K to the plasma membrane
(Figure 4E) and initiate production of PIP3 as measured prerequisite for Rho kinase activation (ROCK). Inhibitors
of src/p62yes similarly antagonized the ICAM-2-induceddirectly by single-cell analysis within primary cells (Fig-
ure 6B) and indirectly through a PDK-1 activity assay tyrosine phosphorylation of Ezrin. Taken together, the
data suggest that ROCK is involved in the activation of(Figure 4F). PIP3 production serves to localize AKT to the
membrane, as translocation is observed as a function of ezrin that leads to its phosphorylation by src/p62yes. We
had noted that ezrin threonine phosphorylation, thoughICAM-2 crosslinking (Figure 4G). The profound effects
of ezrin tyrosine phosphorylation (induced by ICAM-2 initially present, was intensified upon ICAM-2 ligation,
contrasting the induction of ezrin tyrosine phosphoryla-clustering) and inhibition of the ICAM-2 antiapoptotic
effect with Y-27632 and herbimycin A leads us to pro- tion (see Figure 4C) and its ablation in the presence of
(C) PBMC were crosslinked for ICAM-1, -2, -3, CD43, or CD44 (10 g/ml, 45 min) prior to being assessed for phospho-AKTSer473 detection
by flow cytometry and gated for CD19 cells.
(D) PBMC were crosslinked for ICAM-1, -2, -3, CD43, or CD44 (10 g/ml, 45 min) prior to being induced to apoptose as described above.
(E) PBMC was crosslinked for ICAM-2 prior to being induced to apoptose as described above in the presence or absence of inhibitory
compounds Psi-tectorigenin and Y-27632.
(F) CD4 and CD19 mixed lymphocyte reaction. CD19 cells were gated and displayed for analysis of phospho-AKTSer473. Median fluorescence
values are representative of eight independent experiments.  refers to unmixed B cell population.
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inhibitors of Rho-dependent processes (see Figure 5C). ptosis. ICAM-3 crosslinking intensified PIP2 production
in addition to exhibiting a temporal delay in AKT activa-Although this suggests that src/p62yes tyrosine phos-
phorylation of ezrin is upstream of a Rho-dependent tion (data not shown), which differed from ICAM-2 cross-
linking and suggests that ICAM-3 is affecting other yetthreonine phosphorylation, further studies are needed
to be identified signaling pathways. ICAM-1 showed fewto conclusively delineate the temporal kinetics of ezrin
similarities to ICAM-2 signaling. These observations il-activation as induced by ICAM-2 oligomerization.
lustrate that significant similarities and differences dis-We did not find a dependency on PKC isozymes, as
tinguish the intracellular signaling pathways for ICAMsPKC isozyme inhibitors bisindolymaleimide I, bisindoly-
capable of binding the same ERM proteins.maleimide II, and STP did not abrogate the ICAM-2-
The work presented attributes an unrecognized func-induced survival signal and suggest that PKC-depen-
tion for ICAM-2. The finding that ICAM-2 can exert celldent threonine phosphorylation of ezrin for its activation
survival signaling, ectopically and endogenously, as wellas reported by others contributes minimally in this sys-
as elicit an antiapoptotic phenotype in a variety of celltem (Ng et al., 2001). Although we do note an increase
lines and human primary cells, suggests that its deregu-of threonine phosphorylation of ezrin as a function of
lation, or induced clustering, could contribute to theICAM-2 crosslinking (Figure 4C), its basal levels at the
antiapoptotic phenotype that leads to tumor progres-zero time point and difference observed in the fold in-
sion and/or cell survival. Development of antimetastaticduction of tyrosine phosphorylation of ezrin lead us to
approaches targeted to block cancer cell adhesion bybelieve that although the threonine phosphorylation
general blockade of adhesion molecules warrants cau-state may be contributory, ezrin tyrosine phosphoryla-
tion, as the development of such agents may have detri-tion plays a significant role in relaying the ICAM-2-
mental effects in normal physiological process that areinduced signal.
dependent on cell-to-cell contact interaction such asThe PI3K/AKT signaling system is a general mediator
those mediated by ICAM/LFA-1. Thus, pathways in-of extracellular stimuli, including growth factors, cyto-
volved in the regulation of ICAM-2 or other adhesionkines, as well as adhesion to extracellular matrices
molecule expression, distribution, and activation could(Downward, 1998). PIP3 binds to the plecktrin domain
be alternative targets to the development of antitumorof AKT and recruits AKT to the membrane, where it
therapies and, potentially, offer novel immunomodula-becomes dually phosphorylated (Alessi et al., 1996) and
tory targets.is then active and can phosphorylate a number of down-
stream effectors that can contribute to cell survival.
Experimental ProceduresICAM-2-induced activation of AKT kinase resulted in the
activation of several downstream effectors as detected
Antibodies and Chemicalsby phosphorylation of BAD, GSK3, FKHR, and AFX, all
All antibodies were purchased from Cell Signaling Technologiesof which can contribute to favor cell survival (Brunet et
(Beverly, MA) or as indicated. Anti-ICAM-2 IC2/2 mAb and anti-
al., 1999; Zha et al., 1996). These observations support ICAM-2-FITC mAb (IC2/2) were purchased from Research Diagnos-
that ICAM-2 activation would lead to an antiapoptotic tics (Flanders, NJ). Anti-ICAM-2 N-terminal, anti-ICAM-2 C-terminal,
anti--actinin, and secondaries were purchased from Santa Cruzsignal in a variety of cells. A graphical illustration of
Biotechnologies (Santa Cruz, CA). Anti-ezrin mAb and anti-PI3KICAM-2 activating the PI3K/AKT pathway is depicted in
were purchased from Transduction Laboratories (San Diego, CA).Figure 7, although differences in molecular mechanisms
Anti-PDK-phospho-serine, anti-PDK-phospho-threonine, Y-27362,may exist at the ICAM-2/ezrin and ICAM-2/-actinin in-
U0126, bisindolymaleimide I and II, psi-tectorigenin, etoposide,
terface, as alluded above, in different cell types. PD98059, LY294002, TNF, and IL-2 were purchased from Calbio-
Although ICAM-3, CD43, and CD44 induced AKT ac- chem (San Diego, CA). STP, wortmannin, acridine orange, ethidium
bromide, propidium iodide, and GTP	S were purchased from Sigmativity in primary cells as determined by single-cell analy-
(St. Louis, MO). Alexa Flour series secondary antibodies, anti-PIP3,sis, only ICAM-2 and ICAM-3 were able to block apopto-
and anti-PIP2 were purchased from Molecular Probes (Eugene, OR).sis to Fas and TNF, with CD44 and CD43 crosslinking
Annexin-V-FITC was from BD Biosciences (San Jose, CA). CD4-
instigated cell death. The complexity of these results APC, CD19-PerCP, anti-ICAM-1, anti-ICAM-3, anti-CD43, anti-
suggest ICAM-2 and ICAM-3 possess specific functional CD44, ANTI-LFA-1, and anti-MAC-1 were purchased from Phar-
roles for maintaining cell survival that are distinct from Mingen (San Diego, CA). Anti-CD18 integrin mAb (clone TS1/18.1)
and anti-CD11a mAb (TS1.22.1) were purchased from Develop-CD43 and CD44. During the preparation of this work, it
mental Studies Hybridoma Bank (Iowa City, IA). Additional reagentshas been reported that crosslinking of CD44 on synovial
are described where appropriate.cells from rheumatoid arthritis patients can trigger apo-
ptosis (Fujii et al., 2001). Therefore, the specific roles of
Retroviral cDNA Screeningthe CD43 and CD44 molecules in lymphocytes has not
Production and infection of retroviruses was carried out as de-been resolved; however, these studies either support or
scribed (Kitamura et al., 1995). A cDNA library was prepared from
are consistent with the observations reported here that Jurkat T cells in the pBabe-S vector. The library (2  106 primary
crosslinking of CD43 and CD44 initiates apoptosis in transformants) was used to transfect 107 PHOENIX-E packaging
CD19 human cells and that their engagement is conse- cells. The pBMN-LacZ control vector was spiked into the library at
1:10 to monitor the transfection/infection efficiency. Viral superna-quentially distinct from that of ICAM-2 and ICAM-3.
tants were harvested and used to infect107 exponentially growingAs noted, crosslinking of ICAM-3 protected against
NIH3T3 cells; 48 hr postinfection, the cells were split and analyzedapoptosis, representing a functional similarity with
for -galactosidase activity. The library-transduced NIH3T3 cells
ICAM-2. Both ICAM-2 and ICAM-3 increased PIP3. This were plated at 25% confluency; 24 hr later the medium was re-
increase, and not AKT activation per se, was best corre- placed with DMEM containing 1 M STP. After 24 hr treatment,
the STP-containing medium was replaced with complete media.lated with protection from Fas- and TNF-induced apo-
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Surviving cells were allowed to reach 80% confluency (7 days). was made cell permeant by preincubating compound with Fugene
(Roche Biochemicals) in a 1:4 molar ratio (30 min, 25C) prior toSurvivor cells were retreated as described two for additional rounds.
pBMN-Z-IN (vector control) and pBMN-Z-IN-GFP (GFP vector con- being applied to cells (O.D.P., unpublished data).
trol) served as control vectors.
Apoptosis Assays
Phenotypic Transfer Assay Apoptosis was determined either by counting pyknotic nuclei,
An aliquot of the surviving library-infected cells were superinfected annexin-V binding by flow cytometry, or TUNEL BrdU staining by
with Moloney Murine Leukemia Virus (gift of T. Kinsella, Stanford). flow cytometry as indicated. Apoptosis was induced by STP (1 m),
Superinfected cells were passaged for 2 weeks to allow efficient anti-mouse Fas (5 g/ml Santa Cruz Biotechnology (SCB), or anti-
spread of the helper virus. Naive NIH3T3 cells were infected with human Fas (10 ng/ml CH11 Kamiya Biomedical), or as indicated.
viral supernatants and allowed to express for 48 hr. Reinfected cells For pyknotic nuclei count, NIH3T3 cells were grown on glass cov-
were then treated with STP as described above. Surviving cells were erslips and assayed for apoptosis. Suspension cells were analyzed
cultured for 7 days and analyzed for transfer by RT-PCR. by nuclear staining with 25 M acridine orange/25 m ethidium
bromide or 5 g/ml Hoechst 33342 (Molecular Probes, Eugene, OR).
RT-PCR Cloning of Proviral-cDNA Inserts Apoptosis was identified by the presence of characteristic pyknotic
and Construct Generation nuclei as described (Jacobson and Raff, 1995). At least five individ-
RNA was prepared by the acid-guanidium-phenol-chloroform ual fields were photographed and counted using a Zeiss axioscope
method as described (Chomczynski and Sacchi, 1987). cDNA was fluorescence microscope. Trypan blue exclusion assay was used
prepared from 4 g heat-denatured total RNA in a 50 l reaction for survival assay (Figure 3A). Percent survival represents ([number
volume (Promega, Madison, WI) and incubated at 42C and 55C of viable cells posttreatment]/[number of viable cells pretreatment])
for 45 min. The cDNA reaction products (5 l) were amplified (primers: 100. FACS-based annexin-V-FITC/PI staining was done as de-
5-GATCCTCCCTTTATCCAG; 5-GAATGAAAGACCCCACCTGT) scribed (PharMingen). TUNEL assay was performed as described
in a 50 l PCR reaction mix (Perkin-Elmer, Foster City, CA) at 95C/ by manufacturer of Apoptosis BrdU kit (Promega). Flow cytometry
30 s; 55C/60 s; and 72C/2 min for 25 cycles. Full-length ICAM2 data acquisition was performed 24 hr post STP treatment (1 M)
cDNA was cloned into retroviral vector PBM-Z-IN backbone at BamHI/ for both BrdU (10,000 events collected) and pyknotic nuclei count
Sal1 site. ICAM2-C-, ICAM2-N-, and ICAM2-C-terminal scrambled and 12 hr post STP treatment for annexin V binding (100,000 events
were generated by PCR and cloned into the BamHI/Sal1 site. collected). Flow cytometry analysis was performed on a BD FACS-
Calibur machine with CELLQuest and analyzed using FlowJo soft-
ware (Tree Star).Cell Culture and Preparation of Primary Cells
NIH3T3 murine fibroblasts were maintained in DMEM, 10% DCS,
1% PSQ (Duelbecco Modified Eagle Media, 10% Donar calf serum, Kinase Assays
and 1% penicillin-streptomycin [1000 units/ml and 2 mM L-gluta- PDK-1 activity was determined by a PDK-1 immunoprecipitation
mine PSQ]). Jurkat T cells and CH27 B cells were maintained in kinase assay kit (Upstate Biotechnology, Lake Placid, NY) as recom-
RPMI-1640, 10% FCS, and 1% PSQ. BaF3 pro-B cells were main- mended by manufacturer. AKT activity was determined by AKT ac-
tained in RPMI-1640, 10% FCS, 1% PSQ, and 400 U/ml IL-3 (Pepro- tivity assay kit (Cell Signaling Technologies, Boston, MA) as recom-
tech). 70Z/3 pre-B cells were maintained in RPMI-1640, 10% FCS, mended by manufacturer. Assays are representative of three
1% PSQ, and 50m-mercaptoethanol. HL60 cells were maintained independent virally transduced cell populations each repeated three
in Opti-Mem I, 10% FCS, and 1% PSQ. 293T cells were maintained times (n  9) and are represented as standard deviations were
in DMEM, 10% FCS, and 1%PSQ. Cells were maintained at 5% CO2/ appropriate.
37C humidified incubator. Transduced cells were maintained in 500
g/ml G418 (Sigma), and proper expression of construct was verified
Cell Fractionation, Immunoprecipitations, and Immunoblottingby Western blots and FACS analyses of full-length ICAM-2, ICAM-
Triton-X-100 fractionation was carried out as described (Nixon and2C, and ICAM-N as indicated. STP treatment (24 hr, 1 M) (unless
McPhail, 1999). Cell extracts were prepared from 2  106 cells inotherwise indicated). LY294002 treatment (10 M, 30 min) before
lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mMany subsequent treatment. Wortmannin treatment (24 hr, 100 nM).
EGTA, 1% Triton X-100, 2.5 mM Na2PO4, 1 mM -glycerolphosphate,Chemicals were dissolved in DMSO (final being 1:1000 for solvent
1 mM Na3V04, 1g/ml Leupeptin, 1 mM PMSF, and protease inhibitordilution), and vector controls were incubated with 1% DMSO as
cocktail tablet [Boehringer Mannheim]). Extracts were centrifugednegative control. Vector controls consisted of pBMN-Z-IN (empty
14,000 RPM (5 min, 4C) and 20g (BCA protein assay [Pierce]) werevector). The infection frequency of pBMN-Z-IN-GFP was 48% 
immunoblotted using standard procedures. Immunoprecipitations10 for three independent viral transductions. Continual neomycin
were precleared with protein A/G plus-agarose beads (SBC), incu-selection yielded homogenous ICAM-2, ICAM2-C, ICAM2-N, or
bated for 1 hr with primary and 1 hr with protein A/G plus-agarosecontrol vector populations as routinely monitored by flow cytometry
beads, and washed four times with lysis buffer. Blots were incubatedfor protein expression. Primary cells were isolated from human pe-
with the indicated antibodies. HRP-conjugated secondary antibod-ripheral blood by Ficoll-plaque density centrifugation and depleted
ies were used and visualized using ECL detection (Amersham). Blotsof adherent cells. Isolated cells were maintained in complete media
are representative of at least three independent experiments.and analyzed by FACS for CD4, CD3, CD19, and ICAM-2 expression.
Crosslinking Flow Cytometry and FACS Analysis
Intracellular and extracellular staining was performed as describedAntibody crosslinking experiments were performed using mAbs to
anti-ICAM-1, anti-ICAM-2, anti-ICAM-3, anti-CD43, or anti-CD44 (www.metazoa.com\UPL3287) using indicated antibodies. Intracellu-
lar probe for AKT activity was performed as described (Perez andthat recognizes the N-terminal region (extracellular domain) at 10
g/ml. Spin dialysis was used for buffer exchange of azide con- Nolan, 2002). Intracellular probe for PIP3 and PIP2 was made by
conjugating mAb to PIP3 or PIP2 to alexa 488 or alexa 633 (O.D.P.taining antibodies (0.01%) to phosphate buffered saline buffer (pH
7.4). Anti-mouse IgG (Sigma) was used as a control antibody in and G.P.N., unpublished data). Quantitative FACS analysis was per-
formed as described (Iyer et al., 1998). In brief, R-phycoerythrin wascrosslinking experiments. 1 107 Jurkat, BaF3, or PBMC cells were
serum starved for 4 hr, respectively (except PBMC). Cells were conjugated to anti-ICAM2 N-terminal mAb (Research Diagnostics
IC2/2) and quantitated using Quantibrite-PE beads (BD systems).incubated with either mAb or mouse IgG (10 g/ml) at 37C for the
indicated time. Time points began post serum starvation to attenu- Flow cytometry analysis was performed on a BD FACSCalibur ma-
chine and analyzed using FlowJo software (Tree Star). Flow cytome-ate most of the signaling pathways or as indicated. Cells extracts
were taken and subjected to either immunoprecipitation or immu- try data are representative of three independent experiments of 106
cells/sample analyzed. 100,000 events were collected or otherwisenoblotting where appropriate. Primary cells were subjected to apo-
ptotic treatment followed by preparation for flow cytometry. GTP	S noted and calibrated using Calibrite beads (BD systems). Data plot-
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ted in bar graph format is expressed as the mean (bar)  SD of Tonin, P.N. (2000). Allelotyping defines minimal imbalance at chro-
mosomal region 17q25 in non-serous epithelial ovarian cancers.triplicate experiments.
Oncogene 19, 1466–1472.
Lymphocyte Mixing Reaction Downward, J. (1998). Mechanisms and consequences of activation
PBMC were depleted of macrophages, neutrophils, and activated of protein kinase B/Akt. Curr. Opin. Cell Biol. 10, 262–267.
T cells using a combination of biotinylated anti-CD8, anti-CD11b, Frisch, S.M., and Ruoslahti, E. (1997). Integrins and anoikis. Curr.
anti-CD16, anti-CD14, anti-HLA-DR, and anti-CD56 mAbs. Naive Opin. Cell Biol. 9, 701–706.
CD4 T cells were isolated using T cell negative isolation kit (Dynal)
Fujii, K., Fujii, Y., Hubscher, S., and Tanaka, Y. (2001). Cd44 is theand CD19 cells using B cell negative isolation kit (Dynal). CD19
physiological trigger of fas up-regulation on rheumatoid synovialcells and CD4 cells were magnetically sorted and maintained in
cells. J. Immunol. 167, 1198–1203.RPMI/10%FCS/1%PSQ. 1  106 were harvested and either left un-
Gautreau, A., Poullet, P., Louvard, D., and Arpin, M. (1999). Ezrin, atreated, mixed (CD4 and CD19 populations), or incubated with mAbs
plasma membrane-microfilament linker, signals cell survival throughfor LFA-1, MAC-1, and 2-integrin (TS18.1) (CD4 cells) or ICAM-1,
the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad.ICAM-2, and ICAM-3 (CD19 cells) at 4C for 15 min in staining media
Sci. USA 96, 7300–7305.([5 g/ml, 15 min, 4C] deficient RPMI, 4%FCS). Cells were washed
(ice cold PBS, 1 mM EDTA) and resuspended in either mixed or Gerwin, N., Gonzalo, J.A., Lloyd, C., Coyle, A.J., Reiss, Y., Banu, N.,
unmixed conditions in a total volume of 100 l (RPMI, 4%FCS) and Wang, B., Xu, H., Avraham, H., Engelhardt, B., et al. (1999). Prolonged
incubated at 37C (30 min). Samples were then prepared for surface eosinophil accumulation in allergic lung interstitium of ICAM-2 defi-
and intracellular flow cytometry as described above. The experiment cient mice results in extended hyperresponsiveness. Immunity 10,
in Figure 6F is representative of eight independent results from 9–19.
PBMC of four healthy donors. Human PBMC were ICAM-2 cross- Heiska, L., Kantor, C., Parr, T., Critchley, D.R., Vilja, P., Gahmberg,
linked (10 g/ml, 45 min) prior to being subjected to apoptosis by C.G., and Carpen, O. (1996). Binding of the cytoplasmic domain of
treatment with TNF 200 ng/ml plus 1 g/ml cycloheximide) and intercellular adhesion molecule-2 (ICAM-2) to -actinin. J. Biol.
anti-Fas antibody (10 ng/ml CH11) for 12 hr. Data are displayed as Chem. 271, 26214–26219.
median fluorescent intensity of 50,000 events collected, as gated
Helander, T.S., Carpen, O., Turunen, O., Kovanen, P.E., Vaheri, A.,
for CD19 cells.
and Timonen, T. (1996). ICAM-2 redistributed by ezrin as a target
for killer cells. Nature 382, 265–268.
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